secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055610
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q1 2024 net loss $135.6M ($1.33 loss per share); cash $634M; aficamten NDA on track for Q3 2024
--------------------------------------------------------------------------------

- Net loss of $135.6M ($1.33 per share) vs $131.3M loss ($1.38 per share) in Q1 2023.
- Cash and investments $634.3M as of March 31, 2024; revenue fell to $0.8M from $4.6M.
- Aficamten NDA submission planned for Q3 2024; MAA submission to EMA in Q4 2024.
- Initiated enrollment in pediatric HCM trial CEDAR-HCM; MAPLE-HCM enrollment expected to complete Q3 2024.
- Appointed Sung Lee as EVP, CFO effective May 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024055610/0000950170-24-055610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024055610/cytk-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer